The 5alpha-reduction of testosterone in the neuroendocrine structures. Biochemical and physiological implications.
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000378:metabolism*; D000728:Androgens / Q000502:physiology; D015113:Androstane-3,17-diol / Q000502:physiology; D000735:Androstenedione / Q000502:physiology; D000818:Animals; D001717:Birds / Q000378:metabolism; D002369:Castration; D013196:Dihydrotestosterone / Q000502:physiology; D004967:Estrogens / Q000502:physiology; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000378:metabolism; D006065:Gonadotropins, Pituitary / Q000502:physiology; D006801:Humans; D007031:Hypothalamus / Q000201:enzymology; D008027:Light; D008297:Male; D010088:Oxidoreductases / Q000378:metabolism*; D010507:Periodicity; D010870:Pineal Gland / Q000502:physiology; D010903:Pituitary Gland, Anterior / Q000201:enzymology; D011388:Prolactin / Q000378:metabolism; D011944:Receptors, Androgen / Q000502:physiology; D012725:Sexual Behavior; D012741:Sexual Maturation; D013739:Testosterone / Q000378:metabolism; D014667:Vasopressins / Q000378:metabolism / Q000502:physiology
D000728:Androgens; D004967:Estrogens; D006065:Gonadotropins, Pituitary; D011944:Receptors, Androgen; D013196:Dihydrotestosterone; D014667:Vasopressins; D015113:Androstane-3,17-diol; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D000735:Androstenedione; D011388:Prolactin; D010088:Oxidoreductases; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase